Asia Pacific Biosimilars Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Asia Pacific Biosimilars Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Asia Pacific Biosimilars Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising demand for biosimilars due to cost-effectiveness
5.1.2 Expanding use of biosimilars in oncology and immunology

5.2 Market Opportunities

5.2.1 Adoption of biosimilars to lower healthcare costs
5.2.2 Expansion into emerging markets with biosimilar drugs

5.3 Future Trends

5.3.1 Growing adoption of biosimilars
5.3.2 Support for biosimilar approvals

5.4 Impact of Drivers and Restraints

6. Asia Pacific Biosimilars Market Regional Analysis

6.1 Asia Pacific Biosimilars Market Overview

6.2 Asia Pacific Biosimilars Market Revenue 2020-2028 (US$ Million)

6.3 Asia Pacific Biosimilars Market Forecast Analysis

7. Asia Pacific Biosimilars Market Analysis – by Disease Indication

7.1 Cancer

7.1.1 Overview
7.1.2 Cancer: Asia Pacific Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Diabetes

7.2.1 Overview
7.2.2 Diabetes: Asia Pacific Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Autoimmune Diseases

7.3.1 Overview
7.3.2 Autoimmune Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Other Diseases

7.4.1 Overview
7.4.2 Other Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Biosimilars Market Analysis – by Drug Class

8.1 Granulocyte Colony-Stimulating Factors

8.1.1 Overview
8.1.2 Granulocyte Colony-Stimulating Factors: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Human Growth Hormone

8.2.1 Overview
8.2.2 Human Growth Hormone: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.3 Insulin

8.3.1 Overview
8.3.2 Insulin: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.4 TNF Blockers & Monoclonal Antibodies

8.4.1 Overview
8.4.2 TNF Blockers & Monoclonal Antibodies: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Erythropoietin-Stimulating Agents

8.5.1 Overview
8.5.2 Erythropoietin-Stimulating Agents: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Biosimilars Market Analysis – by Route of Administration

9.1 Intravenous

9.1.1 Overview
9.1.2 Erythropoietin-Stimulating Agents: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Subcutaneous

9.2.1 Overview
9.2.2 Erythropoietin-Stimulating Agents: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Biosimilars Market – Asia-Pacific Analysis

10.1 Asia-Pacific

10.1.1 Asia Pacific Biosimilars Market Breakdown, by Key Country, 2023 and 2028 (%)
10.1.1.1 Asia Pacific Biosimilars Market – Revenue and Forecast Analysis – by Country
10.1.1.1 China: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 China: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
10.1.1.1.2 China: Asia Pacific Biosimilars Market Breakdown, by Drug Class
10.1.1.1.3 China: Asia Pacific Biosimilars Market Breakdown, by Route of Administration

10.1.1.2 India: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 India: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
10.1.1.2.2 India: Asia Pacific Biosimilars Market Breakdown, by Drug Class
10.1.1.2.3 India: Asia Pacific Biosimilars Market Breakdown, by Route of Administration

10.1.1.3 Japan: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 Japan: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
10.1.1.3.2 Japan: Asia Pacific Biosimilars Market Breakdown, by Drug Class
10.1.1.3.3 Japan: Asia Pacific Biosimilars Market Breakdown, by Route of Administration

10.1.1.4 Australia: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.4.1 Australia: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
10.1.1.4.2 Australia: Asia Pacific Biosimilars Market Breakdown, by Drug Class
10.1.1.4.3 Australia: Asia Pacific Biosimilars Market Breakdown, by Route of Administration

10.1.1.5 Rest of Asia-Pacific : Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Disease Indication
10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Drug Class
10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Asia Pacific Biosimilars Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Amgen Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Sanofi SA

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Biocon Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Eli Lilly and Co

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Sandoz AG

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Teva Pharmaceutical Industries Ltd

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Pfizer Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Dr. Reddy's Laboratories Ltd

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Celltrion Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Samsung Bioepis Co Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights